A single-dose, randomized, two-period, two-sequence, crossover comparative bioavailability study on formulations containing ramipril, amlodipine and indapamide in combination product versus Triatec® 10 mg capsules (Sanofi - Produtos Farmacêuticos, Lda., Portugal), containing ramipril, Norvasc® 10 mg, tablets (Upjohn EESV, the Netherlands), containing amlodipine and Natrilix® 2.5 mg film-coated tablets (Les Laboratoires Servier, France), containing indapamide co-administered together as reference in healthy male and female volunteers under fasting conditions.

2024-514456-32-00 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 9 Sep 2024 · End 22 Oct 2024 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 72
Countries 1
Sites 1

hypertension

Key facts

Sponsor
Zaklady Farmaceutyczne Polpharma S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
9 Sep 2024 → 22 Oct 2024
Decision date (initial)
2024-07-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

hypertension

VersionLevelCodeTermSystem organ class
21.1 PT 10015488 Essential hypertension 100000004866

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Zaklady Farmaceutyczne Polpharma S.A.

Sponsor organisation
Zaklady Farmaceutyczne Polpharma S.A.
Address
Ul. Pelplinska 19
City
Starogard Gdanski
Postcode
83-200
Country
Poland

Scientific contact point

Organisation
Zaklady Farmaceutyczne Polpharma S.A.
Contact name
Clinical R&D

Public contact point

Organisation
Zaklady Farmaceutyczne Polpharma S.A.
Contact name
Clinical R&D

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 72 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Cepha s.r.o.
clinic, Komenskeho 19, Severni Predmesti, Plzen 1

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2024-09-09 2024-10-22 2024-09-09 2024-09-16

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-04 Czechia Acceptable
2024-07-30
2024-07-30